$SLDB
Solid Biosciences Inc.

2022 Q1 Form 10-Q Financial Statement

#000156459022015867 Filed on April 27, 2022

View on sec.gov

Income Statement

Concept 2022 Q1 2021 Q1
Revenue $1.925M $3.340M
YoY Change -42.37%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $7.352M $6.020M
YoY Change 22.13% 14.67%
% of Gross Profit
Research & Development $19.95M $14.21M
YoY Change 40.4% -27.78%
% of Gross Profit
Depreciation & Amortization $709.0K $734.0K
YoY Change -3.41% -28.46%
% of Gross Profit
Operating Expenses $27.30M $20.22M
YoY Change 34.99% -24.71%
Operating Profit -$25.37M
YoY Change
Interest Expense -$14.00K
YoY Change -108.54%
% of Operating Profit
Other Income/Expense, Net $44.00K -$14.00K
YoY Change -414.29% -108.48%
Pretax Income -$25.33M -$16.90M
YoY Change 49.87% -36.68%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$25.33M -$16.90M
YoY Change 49.87% -36.69%
Net Earnings / Revenue -1315.74% -505.99%
Basic Earnings Per Share -$3.37
Diluted Earnings Per Share -$224.9K -$189.3K
COMMON SHARES
Basic Shares Outstanding 7.507M
Diluted Shares Outstanding 7.507M

Balance Sheet

Concept 2022 Q1 2021 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $180.1M $268.5M
YoY Change -32.94% 400.93%
Cash & Equivalents $129.7M $268.5M
Short-Term Investments $50.34M
Other Short-Term Assets $18.54M $5.500M
YoY Change 237.16% 27.91%
Inventory
Prepaid Expenses
Receivables $14.00K $300.0K
Other Receivables $0.00 $0.00
Total Short-Term Assets $198.6M $274.3M
YoY Change -27.59% 373.74%
LONG-TERM ASSETS
Property, Plant & Equipment $6.097M $7.461M
YoY Change -18.28% -51.86%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $2.129M $300.0K
YoY Change 609.67% -40.0%
Total Long-Term Assets $8.948M $10.98M
YoY Change -18.54% -31.78%
TOTAL ASSETS
Total Short-Term Assets $198.6M $274.3M
Total Long-Term Assets $8.948M $10.98M
Total Assets $207.6M $285.3M
YoY Change -27.24% 285.51%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $4.761M $3.194M
YoY Change 49.06% 33.08%
Accrued Expenses $9.440M $6.794M
YoY Change 38.95% -34.04%
Deferred Revenue $6.170M $10.66M
YoY Change -42.13%
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $239.0K $200.0K
YoY Change 19.5% 0.0%
Total Short-Term Liabilities $21.74M $22.80M
YoY Change -4.63% 76.74%
LONG-TERM LIABILITIES
Long-Term Debt $231.0K $500.0K
YoY Change -53.8% -28.57%
Other Long-Term Liabilities $70.00K $9.000M
YoY Change -99.22% 130.77%
Total Long-Term Liabilities $301.0K $9.500M
YoY Change -96.83% 106.52%
TOTAL LIABILITIES
Total Short-Term Liabilities $21.74M $22.80M
Total Long-Term Liabilities $301.0K $9.500M
Total Liabilities $22.05M $32.30M
YoY Change -31.75% 84.57%
SHAREHOLDERS EQUITY
Retained Earnings -$502.1M -$421.5M
YoY Change 19.13%
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $185.5M $253.0M
YoY Change
Total Liabilities & Shareholders Equity $207.6M $285.3M
YoY Change -27.24% 285.51%

Cashflow Statement

Concept 2022 Q1 2021 Q1
OPERATING ACTIVITIES
Net Income -$25.33M -$16.90M
YoY Change 49.87% -36.69%
Depreciation, Depletion And Amortization $709.0K $734.0K
YoY Change -3.41% -28.46%
Cash From Operating Activities -$27.19M -$21.37M
YoY Change 27.26% -27.01%
INVESTING ACTIVITIES
Capital Expenditures $184.0K $35.00K
YoY Change 425.71% -94.86%
Acquisitions
YoY Change
Other Investing Activities $37.93M $0.00
YoY Change -100.0%
Cash From Investing Activities $37.74M -$35.00K
YoY Change -107937.14% -100.55%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $135.1M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 22.00K 135.2M
YoY Change -99.98%
NET CHANGE
Cash From Operating Activities -27.19M -21.37M
Cash From Investing Activities 37.74M -35.00K
Cash From Financing Activities 22.00K 135.2M
Net Change In Cash 10.58M 113.8M
YoY Change -90.7% -597.69%
FREE CASH FLOW
Cash From Operating Activities -$27.19M -$21.37M
Capital Expenditures $184.0K $35.00K
Free Cash Flow -$27.37M -$21.40M
YoY Change 27.91% -28.56%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q4 us-gaap Accounts Receivable Related Parties Current
AccountsReceivableRelatedPartiesCurrent
110000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
6462000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1142000
CY2021Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
35000
CY2022Q1 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
6170000
CY2021Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
8080000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
23601000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
275000
CY2021Q4 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
293000
CY2021Q1 us-gaap Revenue From Related Parties
RevenueFromRelatedParties
3335000
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-25372000
CY2022Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-6000
CY2021Q1 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-16900000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2612000
CY2022Q1 sldb Pre Funded Warrants Exercise During Period Value
PreFundedWarrantsExerciseDuringPeriodValue
22000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
185511000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
132086000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2907000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
8872000
CY2021Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
134878000
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
29000
CY2021Q1 us-gaap Profit Loss
ProfitLoss
-16900000
CY2021Q1 us-gaap Profit Loss
ProfitLoss
-16900000
CY2022Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-371000
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
2612000
CY2021Q1 us-gaap Share Based Compensation
ShareBasedCompensation
2907000
CY2022Q1 us-gaap Depreciation
Depreciation
709000
CY2021Q1 us-gaap Depreciation
Depreciation
734000
CY2021Q1 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-3000
CY2022Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
3366000
CY2021Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
769000
CY2022Q1 us-gaap Increase Decrease In Accounts Receivable Related Parties
IncreaseDecreaseInAccountsReceivableRelatedParties
-96000
CY2021Q1 us-gaap Increase Decrease In Accounts Receivable Related Parties
IncreaseDecreaseInAccountsReceivableRelatedParties
280000
CY2022Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
71000
CY2021Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-90000
CY2022Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-445000
CY2021Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-3916000
CY2022Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-1910000
CY2021Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-3055000
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-27190000
CY2021Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-21366000
CY2022Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
184000
CY2021Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
35000
CY2022Q1 us-gaap Payments For Proceeds From Availableforsale Securities Shortterm
PaymentsForProceedsFromAvailableforsaleSecuritiesShortterm
-46808000
CY2022Q1 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
8881000
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
37743000
CY2021Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-35000
CY2021Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
135125000
CY2022Q1 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
22000
CY2021Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
29000
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
22000
CY2021Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
135154000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
10575000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
113753000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
121206000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
155071000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
131781000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
268824000
CY2021Q1 sldb Offering Costs In Accruals
OfferingCostsInAccruals
247000
CY2022Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
264000
CY2021Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
10000
CY2022Q1 sldb Mission Description
MissionDescription
The Company’s mission is to cure Duchenne muscular dystrophy (“Duchenne”), a genetic muscle-wasting disease predominantly affecting boys.
CY2022Q1 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
180050000
CY2021Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
2070000
CY2022Q1 sldb Medicine Description
MedicineDescription
In March 2022, the Company reported two-year interim safety and efficacy data from the first three patients treated with SGT-001 in the 2E14 vg/kg dose cohort of IGNITE DMD, which results suggested durable benefit compared with natural history trajectories 24 months post-administration of SGT-001 across functional, pulmonary and patient reported outcome measures. In addition, no new drug-related safety findings have been identified in patients treated with SGT-001 in IGNITE DMD in post-dosing periods of 90 days to approximately four years. In April 2022, the Company announced that it had concluded enrollment in IGNITE DMD.
CY2022Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-502085000
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-25328000
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-27190000
CY2022Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of the Company’s condensed consolidated financial statements in conformity with GAAP requires management to make estimates, judgments and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, estimates related to revenue recognition, the recognition of research and development expenses and equity-based compensation. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ from the Company’s estimates. </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The full extent to which the COVID-19 pandemic will directly or indirectly impact the Company’s business, results of operations and financial condition, including clinical trials and employee-related amounts, will depend on future developments that are highly uncertain, including new information that may emerge concerning COVID-19 and the actions taken to contain it or treat its impact. The Company has made estimates of the impact of COVID-19 within its financial statements and there may be changes to those estimates in future periods. Actual results could differ from the Company’s estimates. </p>
CY2022Q1 us-gaap Deposit Assets
DepositAssets
2070000
CY2021Q4 us-gaap Deposit Assets
DepositAssets
2070000
CY2022Q1 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
2070000
CY2021Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
2070000
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
129711000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
154744000
CY2022Q1 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
2070000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
119136000
CY2021Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
268497000
CY2021Q1 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
327000
CY2020Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
327000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
131781000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
121206000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
268824000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
155071000
CY2022Q1 us-gaap Related Party Costs
RelatedPartyCosts
235000
CY2021Q1 us-gaap Related Party Costs
RelatedPartyCosts
85000
CY2020Q4 sldb Common Stock Shares Issued Warrant To Purchase
CommonStockSharesIssuedWarrantToPurchase
30000
CY2020Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
3.29
CY2022Q1 sldb Agreement Termination Period
AgreementTerminationPeriod
P60D
CY2022Q1 sldb Agreement Written Notice Period
AgreementWrittenNoticePeriod
P30D
CY2022Q1 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
71287000
CY2022Q1 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
50339000
CY2022Q1 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
121626000
CY2021Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
75224000
CY2021Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
88643000
CY2021Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
163867000
CY2022Q1 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2022Q1 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
CY2021Q4 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2021Q4 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
CY2021 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
0
CY2021 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
0
CY2022Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
0
CY2022Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
0
CY2022Q1 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
50390000
CY2022Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
51000
CY2022Q1 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
50339000
CY2021Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
88688000
CY2021Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
45000
CY2021Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
88643000
CY2022Q1 us-gaap Available For Sale Securities Debt Maturities Next Rolling Twelve Months Amortized Cost Basis
AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsAmortizedCostBasis
50390000
CY2022Q1 us-gaap Available For Sale Securities Debt Maturities Next Rolling Twelve Months Fair Value
AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue
50339000
CY2022Q1 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
50390000
CY2022Q1 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
50339000
CY2022Q1 sldb Available For Sale Securities Weighted Average Maturity Period
AvailableForSaleSecuritiesWeightedAverageMaturityPeriod
P0Y8M12D
CY2021Q4 us-gaap Available For Sale Securities Debt Maturities Next Rolling Twelve Months Amortized Cost Basis
AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsAmortizedCostBasis
88688000
CY2021Q4 us-gaap Available For Sale Securities Debt Maturities Next Rolling Twelve Months Fair Value
AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue
88643000
CY2021Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
88688000
CY2021Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
88643000
CY2021 sldb Available For Sale Securities Weighted Average Maturity Period
AvailableForSaleSecuritiesWeightedAverageMaturityPeriod
P0Y8M12D
CY2022Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
18468000
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
18123000
CY2022Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
12371000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
11661000
CY2022Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
6097000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
6462000
CY2022Q1 us-gaap Depreciation
Depreciation
709000
CY2021Q1 us-gaap Depreciation
Depreciation
734000
CY2022Q1 sldb Prepaid Research And Development Expenses Current
PrepaidResearchAndDevelopmentExpensesCurrent
7697000
CY2021Q4 sldb Prepaid Research And Development Expenses Current
PrepaidResearchAndDevelopmentExpensesCurrent
6015000
CY2022Q1 sldb Prepaid Expense And Other Assets Miscellaneous Current
PrepaidExpenseAndOtherAssetsMiscellaneousCurrent
10847000
CY2021Q4 sldb Prepaid Expense And Other Assets Miscellaneous Current
PrepaidExpenseAndOtherAssetsMiscellaneousCurrent
8708000
CY2022Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
18544000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
14723000
CY2022Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
9440000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
9528000
CY2022Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-25328000
CY2021Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-16900000
CY2022Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
112607322
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2621075
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2397495
CY2022Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2612000
CY2021Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2907000
CY2022Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2021Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2022Q1 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2021Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
89267194
CY2022Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.22
CY2021Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.19
CY2022Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
10050933
CY2021Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5422452

Files In Submission

Name View Source Status
0001564590-22-015867-index-headers.html Edgar Link pending
0001564590-22-015867-index.html Edgar Link pending
0001564590-22-015867.txt Edgar Link pending
0001564590-22-015867-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
sldb-10q_20220331.htm Edgar Link pending
sldb-10q_20220331_htm.xml Edgar Link completed
sldb-20220331.xsd Edgar Link pending
sldb-20220331_cal.xml Edgar Link unprocessable
sldb-20220331_def.xml Edgar Link unprocessable
sldb-20220331_lab.xml Edgar Link unprocessable
sldb-20220331_pre.xml Edgar Link unprocessable
sldb-ex311_11.htm Edgar Link pending
sldb-ex312_8.htm Edgar Link pending
sldb-ex321_9.htm Edgar Link pending
sldb-ex322_10.htm Edgar Link pending